January 9, 2018 / 12:21 PM / in 7 months

BRIEF-FDA Clears Pluristem’s Expanded Access Program To Initiate Treatments Of Critical Limb Ischemia

Jan 9 (Reuters) - Pluristem Therapeutics Inc:

* PLURISTEM THERAPEUTICS - U.S. ‍FDA CLEARED CO’S EXPANDED ACCESS PROGRAM FOR USE OF PLX-PAD CELL TREATMENT IN PATIENTS WITH CRITICAL LIMB ISCHEMIA​

* FDA CLEARS PLURISTEM’S EXPANDED ACCESS PROGRAM TO INITIATE TREATMENTS OF CRITICAL LIMB ISCHEMIA OUTSIDE OF ONGOING PHASE III STUDY Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below